Boult Wade Tennant
Bulletins » First Court of Appeal decision issued on validity of UPC opt outs

On 4 June 2024 the UPC Court of Appeal provided their first decision on the validity of opt outs in the case of Neo Wireless v Toyota (UPC_CoA_79/2024)1. The Court confirmed that for an opt out to be valid and effective it must be filed by or on behalf of all proprietors of all of the national parts of the European patent.

In the case at issue, an opt out had been filed by Neo Wireless LLC (‘Neo USA’) on 30 March 2023, before grant of the application. However, earlier on 7 March 2023 the German national part of the application had been transferred to Neo Wireless GmbH & Co KG (‘Neo Germany’) by way of an assignment. Importantly, the opt out was filed only by Neo USA and the opt out was not filed on behalf of Neo Germany or with their consent. After grant, Toyota Motor Europe NV/SA filed a revocation action at the UPC.

In reply Neo USA argued that their earlier opt out prevented the UPC considering the case. In their view Article 83(3) of the Unified Patent Court Agreement (UPCA) gave the right to “a proprietor” or “an applicant” to file an opt out and it would be wrong to force a proprietor or applicant into the jurisdiction of the UPC “against their will” just because another proprietor or applicant did not consent to the opt out. While Neo USA agreed that Rule 5.1(a) clearly requires that all proprietors or applicants lodge the application to opt out, they argued that the Rule must be ignored as being incompatible with Article 83(3) UPCA which must take precedence.

The Court of Appeal held that the opt out was invalid. The Court noted that the wording of Article 83(3) UPCA was not in itself clear on this issue. However, the UPC was clear that an opt out must apply to all national parts of the European patent. Taking into account the object and purpose of the UPC system – which was to set up a new legal forum that is the default jurisdiction for litigating European patents – the Court held that allowing one proprietor or applicant that only owned some of the national parts of the European patent to opt out all of the national parts would deprive the other proprietors from their use of the UPC against their will. Therefore, in the absence of agreement between all of the proprietors the default situation must remain – that is the UPC having jurisdiction. The result was that the opt out was invalid since the proprietor of the German national part had not filed or consented to the opt out.

The outcome of this case, while not surprising to most practitioners familiar with the UPC, is a timely reminder of the importance of ensuring, when filing an opt out, that the opt out is lodged by or on behalf of all of the true proprietors of the European patent or application. It should also be remembered that the true proprietors are those entitled to be registered as such in the national registers or the EPO register. Therefore, great care must be exercised when opting out European patents or applications where assignments (possibly as yet unrecorded) have previously been executed.

1  Neo Wireless v Toyota (UPC_CoA_79/2024)

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications
Relevant sectors